Top listed pharmaceutical companies have engaged in the ‘speed battle’over the next generation antiulcer drug

CJ Healthcare, Yuhan Corporation and Dawwoong Pharmaceutical are engaged in a speed battle over the P-CAB-type (Potassium Competitive Acid Blocker) drug, receivingattention as the next generation antiulcer drug.

The PPI drug currently dominating in the antiulcer drug market has the following drawbacks: slow manifestation times that requires the 4-hour remedial manifestation time due to its lim...